Koppel Adam bought KLRA

April 20, 2026 · Form 4 insider transaction

Koppel Adam bought 4,145,768 shares of Kailera Therapeutics, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Acquired (buy-side)
Shares
4,145,768
Price
N/A
Total value
N/A
RoleDirector, 10% owner
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateApril 20, 2026
Filing dateApril 20, 2026
Shares owned after21,020,768
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.; Represents securities held directly by BCLS Fund IV Investments, LP ("BCLS Fund IV Investments").; Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

View the original Form 4 on SEC EDGAR
Koppel Adam bought KLRA: April 20, 2026 | Insider Trading Screener